AbbVie and RemeGen have entered into an exclusive global licensing agreement to develop and commercialise RC148, an investigational bispecific antibody for cancer treatment. Under the agreement, AbbVie will hold rights to RC148 outside Greater Ch...
Metropolis Healthcare launches Centre of Genomics, offering advanced sequencing, precision medicine, AI-driven insights, and clinically integrated genomic diagnostics in India.
Jubilant Biosys opens new Noida facility, doubling chemistry capacity for discovery and scale-up, offering FFS contracts, pilot plants, and end-to-end drug discovery solutions.
.jpeg "Aragen Launches CHOMax for Fast DNA to IND Clinical Supply")
Aragen launches CHOMax, a cell line and early manufacturing platform, taking monoclonal antibody programmes from DNA to IND-enabling clinical supply in 10 months.
Novartis to build its fourth US radioligand therapy facility in Florida, boosting RLT supply, ensuring timely cancer treatment, and expanding its $23 billion US investment.
Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration for its supplemental Abbreviated New Drug Application (sANDA) for Bosutinib tablets, 400 mg, strengthening the company’s US oncology generics market pre...
.png "Lupin to Launch Bofanglutide in India for Diabetes & Obesity")
Lupin Limited has signed an exclusive license, supply, and distribution agreement to commercialize Bofanglutide in India, marking a major step in the battle against type 2 diabetes and obesity. Under the pact with China’s Gan&Lee Pharmaceuticals...
Aurobindo Pharma pegfilgrastim biosimilar has received a major boost after the company’s wholly owned biosimilars subsidiary, CuraTeQ Biologics, secured regulatory clearance in Canada. Canadian health regulator, Health Canada has issued a Notice...
Teva Pharmaceuticals has signed a major funding agreement with Royalty Pharma worth up to $500 million, marking a significant boost for the development of TEV-408, its experimental anti-IL-15 antibody...
Merck & Co. has initiated KANDLELIT-007, a global Phase 3 clinical trial evaluating its investigational oral KRAS G12C inhibitor calderasib (MK-1084) in combination with KEYTRUDA QLEX™, a subcutaneous formulation of pembrolizumab with berahyalur...
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")